Literature DB >> 24030385

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

Asim Saha1, Kazutoshi Aoyama, Patricia A Taylor, Brent H Koehn, Rachelle G Veenstra, Angela Panoskaltsis-Mortari, David H Munn, William J Murphy, Miyuki Azuma, Hideo Yagita, Brian T Fife, Mohammed H Sayegh, Nader Najafian, Gerard Socie, Rafi Ahmed, Gordon J Freeman, Arlene H Sharpe, Bruce R Blazar.   

Abstract

Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, play an important role in the maintenance of peripheral tolerance. We explored the role of PD-1 ligands in regulating graft-versus-host disease (GVHD). Both PD-L1 and PD-L2 expression were upregulated in the spleen, liver, colon, and ileum of GVHD mice. Whereas PD-L2 expression was limited to hematopoietic cells, hematopoietic and endothelial cells expressed PD-L1. PD-1/PD-L1, but not PD-1/PD-L2, blockade markedly accelerated GVHD-induced lethality. Chimera studies suggest that PD-L1 expression on host parenchymal cells is more critical than hematopoietic cells in regulating acute GVHD. Rapid mortality onset in PD-L1-deficient hosts was associated with increased gut T-cell homing and loss of intestinal epithelial integrity, along with increased donor T-cell proliferation, activation, Th1 cytokine production, and reduced apoptosis. Bioenergetics profile analysis of proliferating alloreactive donor T-cells demonstrated increased aerobic glycolysis and oxidative phosphorylation in PD-L1-deficient hosts. Donor T-cells exhibited a hyperpolarized mitochondrial membrane potential, increased superoxide production, and increased expression of a glucose transporter in PD-L1-deficient hosts. Taken together, these data provide new insight into the differential roles of host PD-L1 and PD-L2 and their associated cellular and metabolic mechanisms controlling acute GVHD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24030385      PMCID: PMC3811178          DOI: 10.1182/blood-2013-05-500801

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

Authors:  Lieping Chen
Journal:  Nat Rev Immunol       Date:  2004-05       Impact factor: 53.106

2.  Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.

Authors:  Eric F Tewalt; Jarish N Cohen; Sherin J Rouhani; Cynthia J Guidi; Hui Qiao; Shawn P Fahl; Mark R Conaway; Timothy P Bender; Kenneth S Tung; Anthony T Vella; Adam J Adler; Lieping Chen; Victor H Engelhard
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

3.  The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.

Authors:  Shoba Amarnath; Courtney W Mangus; James C M Wang; Fang Wei; Alice He; Veena Kapoor; Jason E Foley; Paul R Massey; Tania C Felizardo; James L Riley; Bruce L Levine; Carl H June; Jeffrey A Medin; Daniel H Fowler
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

4.  Early intestinal Th1 inflammation and mucosal T cell recruitment during acute graft-versus-host reaction.

Authors:  D Snider; H Liang
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

5.  CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.

Authors:  Richard V Parry; Jens M Chemnitz; Kenneth A Frauwirth; Anthony R Lanfranco; Inbal Braunstein; Sumire V Kobayashi; Peter S Linsley; Craig B Thompson; James L Riley
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

Review 6.  Mitochondrial reactive oxygen species-mediated signaling in endothelial cells.

Authors:  David X Zhang; David D Gutterman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-01-19       Impact factor: 4.733

7.  Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.

Authors:  Sigrid E Sandner; Michael R Clarkson; Alan D Salama; Alberto Sanchez-Fueyo; Christoph Domenig; Antje Habicht; Nader Najafian; Hideo Yagita; Miyuki Azuma; Laurence A Turka; Mohamed H Sayegh
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

8.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.

Authors:  Yvette E Latchman; Spencer C Liang; Yin Wu; Tatyana Chernova; Raymond A Sobel; Martina Klemm; Vijay K Kuchroo; Gordon J Freeman; Arlene H Sharpe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

9.  Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography.

Authors:  Matthias Stelljes; Sven Hermann; Jörn Albring; Gabriele Köhler; Markus Löffler; Christiane Franzius; Christopher Poremba; Verena Schlösser; Sarah Volkmann; Corinna Opitz; Christoph Bremer; Torsten Kucharzik; Gerda Silling; Otmar Schober; Wolfgang E Berdel; Michael Schäfers; Joachim Kienast
Journal:  Blood       Date:  2007-12-05       Impact factor: 22.113

10.  CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.

Authors:  P A Taylor; R J Noelle; B R Blazar
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

View more
  87 in total

Review 1.  Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

Authors:  Miguel-Angel Perales; Craig S Sauter; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-17       Impact factor: 5.742

2.  Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation.

Authors:  Brian G Engelhardt; Sophie Paczesny; Dae Kwang Jung; Etienne Daguindau; Madan Jagasia; Bipin N Savani; Wichai Chinratanalab; Robert F Cornell; Stacey Goodman; John P Greer; Adetola A Kassim; Salyka Sengsayadeth; Sandra M Yoder; Michael T Rock; James E Crowe
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

Review 3.  T cell metabolic reprogramming and plasticity.

Authors:  Maria Slack; Tingting Wang; Ruoning Wang
Journal:  Mol Immunol       Date:  2015-08-12       Impact factor: 4.407

4.  Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells in vitro.

Authors:  Yan-Ping Zhu; Feng Yue; Yong He; Peng Li; Yuan Yang; Yu-Ting Han; Yan-Fang Zhang; Guo-Peng Sun; Dong-Guang Guo; Mei Yin; Xuan-Nian Wang
Journal:  Can J Vet Res       Date:  2017-04       Impact factor: 1.310

Review 5.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

Review 6.  Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.

Authors:  Reid W Merryman; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

7.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

8.  B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.

Authors:  Ruishu Deng; Kaniel Cassady; Xiaofan Li; Sheng Yao; Mingfeng Zhang; Jeremy Racine; Jeffrey Lin; Lieping Chen; Defu Zeng
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

9.  The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function.

Authors:  Andrew N Macintyre; Valerie A Gerriets; Amanda G Nichols; Ryan D Michalek; Michael C Rudolph; Divino Deoliveira; Steven M Anderson; E Dale Abel; Benny J Chen; Laura P Hale; Jeffrey C Rathmell
Journal:  Cell Metab       Date:  2014-06-12       Impact factor: 27.287

Review 10.  PD-1 as an immune modulatory receptor.

Authors:  Sheng Yao; Lieping Chen
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.